Correlation Between Copeptin and PSI with Intravenous to Oral Antibiotic Switch Theraphy and Length of Stay in Community-Acquired Pneumonia

Risky Irawan, Reviono Reviono, Harsini Harsini


Background: Pneumonia is a world’s health problem. AVP level in the circulation is difficult to measure therefore copeptin is chosen since
it is more comparable in number and more stable.
Method: Prospective observational study on 25 patients with community-acquired pneumonia in Dr.Moewardi Hospital from July-August 2017.
Result: There were no significant differences between switch therapy duration and length of stay to subject’s characteristic. There was a positive and significant correlation of PSI score to switch therapy and length of stay with a medium to strong correlation strength. Copeptin to switch therapy and length of stay had a positive and significant correlation with a medium to strong correlation strength. Pneumonia patients with PSI Score >90 had a risk of 36.67 times higher with switch therapy duration >4 days and it could be used as a predictor of switch therapy duration. Copeptin >17.23 with switch theraphy duration >4 days on pneumonia patient had a risk of 24.75 times higher and it could be used as a predictor of switch therapy duration. Pneumonia’s patient with PSI Score >100 with length of stay >10 days had a risk of 26.00 times higher and it could be used as a predictor of length of stay. Copeptin >27.39 with length of stay >10 days on pneumonia’s patient had a risk of 36.00 times higher and it could be used as a predictor of length of stay.
Conclusion: Both PSI Score and copeptin level had positive and significant correlation to switch theraphy and length of stay. (J Respir Indo 2019; 39(1): 44-53)


Community Acquired Pneumonia, Copeptin, PSI Score, Switch Theraphy, Length of Stay

Full Text:



Engel MF, Postma DF, Hulscher ME, Teding van berkhout F, Emmelot-Vonk MH, Sankatsing S, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J. 2013;41(1):123-30.

Tores A, Menendez R, Wunderink RG. Bacterial pneumonia and lung abcess. In: Mason RJ, Ernst JD, King TE, Lazrus S, Murray JF, Nadel JA, et al, editors. Murray & Nadel’s textbook of respiratory medicine. 6th ed. Philadelphia: Elsevier; 2016. p.557-82.

Rofiq A, Karyana M, Azhar K, Syarif AK, Indah RM. Penyakit menular. In: Riset kesehatan dasar 2013. p. 65-71.

Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358(7):716-27.

Stoeckel DA, Matuschak GM. Management of pneumonias. In: Lechner AJ, Matuschak GM, Brink DS, editors. Respiratory an integrated approach to disease. 1st ed. New York: Mc Graw Hill; 2011. p.345-53.

Mattila JT, Fine MJ, Limper AH, Murray PR, Chen BB, Lin PL. Pneumonia: treatment and diagnosis. Ann Am Thorac Soc. 2014;11:S189-92.

Marrie TJ. Community acquired pneumonia: clinical features and outcomes. In: Marrie TJ, editor. Community­acquired pneumonia. 1st ed. Canada: Kluwer’s; 2002. p.29-33.

Qu JM, Summah H. Biomarkers: a definite plus in pneumonia. Mediators Inflamm. 2009;2009:675753.

Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community­acquired pneumonia. Crit Care. 2010;14:203.

Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10:7.

Itoi K, Jiang YQ, Iwasaki Y, Watson SJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol. 2004;16(4):348-55.

Ratnayake U, Quinn T, Walker DW, Dickinson H. Cytokines and the neurodevelopmental basis of mental illness. Front Neurosci. 2013;7:1-9.

Dobsa L, Edozien KC. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Med (Zagreb). 2013;23(2):172-90.

Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-9.

Aliberti S, Giuliani F, Ramirez J, Blasi F. How to choose the duration of antibiotic therapy in patients with pneumonia. Curr Opin Infect Dis. 2015;28(2):177-84.

Ramirez JA. Switch therapy in community­acquired pneumonia. Diagn Microbiol Infect Dis. 1995;22(1-2):219-23.

Perhimpunan Dokter Paru Indonesia. Pneumonia komunitas. Pedoman diagnosis dan penatalaksanaan di Indonesia. Balai Penerbit FKUI. Jakarta. 2014.

Dewantara A, Suradi, Reviono, Rima A, Harsini, Aphridasari J. Pengaruh pemberian zink selama 5 hari terhadap kadar endothelin-1, tumor necrosis factor-α dan perbaikan klinis penderita pneumonia. J Respir Indo. 2017;37:8-14.

Menendez R, Zalacain R, Torres A, Cellis R, Esteban L, Blanguer R, et al. Community- acquiered pneumonia in the elderly: Spanish multicenter study. Eur Respir J. 2003;21(2):294-302.

Engel MF, Postma D, Hulscher ME, Teding van Berkhout F, Emmelet-Vonk MH, Sankatsing S, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J. 2013;41(1):123-130.

Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37(2):145-52.

Woodhead M. Treatment of community­acquired pneumonia. In: Marrie TJ, editor. Community-acquired pneumonia. 1st ed. Canada: Kluwer’s; 2002. p.163-75.

Castro­Guardiola A, Vieljo­Rodriguez AL, Soler­ Simon S, Armengou-Arxé A, Bisne-Company V, Peñarroja­Matutano G, et al. Efficacy and safety of oral and early-switch therapy for community acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111(5):367-74.

Nathwani D, Lawson W, Dryden M, Stephens J, Corman S, Solem C, et all. Implementing criteria- based early switch/early discharge programmes: a European perspective. Clin Microbiol Infect. 2015;21:S47-55.

Katan M, Müller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care. 2008;12(2):111-7.

Elshafei A, Abdalla G, El­Motaal OA, Salman T. Copeptin: a neuroendocrine biomarker in acute myocardial infarction. Annu Res Rev Biol. 2013;3(4):1040-54.

Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community­acquired pneumonia : a state-of-the-art review. Clinics (Sao Paulo). 2012;67(11):1321-5.

Abdel-Fattah M, Meligy B, El-Sayed R, El- Naga YA. Serum copeptin level as a predictor of outcome in pneumonia. Indian Pediatr. 2015;52(9):807-8.

Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014;52(10):1447-56.

Marrie TJ. Acute bronchitis and community- acquired pneumonia. In: Fishman AP, Jack AE, Jay AF, Michael AG, Robert MS, Allan IP, editors. Fishman’s pulmonary diseases and disorders. 5th ed. New York: McGraw­Hill Medical; 2008. p.1966-81.



  • There are currently no refbacks.

Copyright (c) 2019 Jurnal Respirologi Indonesia


SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 


Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License